Postmarketing safety reports for the collagenase-based product Xiaflex [Xiapex] show no unexpected findings,
- PDF / 136,303 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 91 Downloads / 181 Views
1
■ Postmarketing safety reports for the collagenasebased product Xiaflex [Xiapex] show no unexpected findings, according to developer BioSpecifics Technologies Corp. and strategic partner Auxilium Pharmaceuticals. Adverse events reports received during the first 30 months after approval of Xiaflex in the US for the treatment of Dupuytren’s contracture in adults showed no clinically meaningful differences in its tolerability profile compared with clinical trials. Between 2 February 2010 and 31 July 2012, 1454 adverse events were reported among the approximately 21 000 patients in the US who received a total of approximately 27 000 injections of Xiaflex. The most common events were laceration, peripheral edema and bruising. BioSpecifics Technologies Corp. BioSpecifics Technologies Corp. Announces 30 Month Safety Update for XIAFLEX(Rm) in Dupuytren’s Contracture Media Release : 5 Sep 2012. Available from: URL: http:// 809140919 www.biospecifics.com
0114-9954/10/1420-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 22 Sep 2012 No. 1420
Data Loading...
